



RE: Papillary Thyroid Carcinoma Treated with Radiofrequency Ablation in a Patient with Hypertrophic Cardiomyopathy: A Case Report

Eun-Kyung Kim, MD, PhD

Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 03722, Korea

Keywords: *Papillary thyroid carcinoma; Radiofrequency catheter ablation*

Dear Editor:

I read with great interest the case report by Sun et al. (1), entitled "Papillary thyroid carcinoma treated with radiofrequency ablation in a patient with hypertrophic cardiomyopathy: a case report," which was published in the Korean Journal of Radiology (KJR), July 2016. The authors presented a subcentimetric papillary thyroid carcinoma treated by radiofrequency ablation in an inoperable condition.

In the case report, a 52-year-old woman had 9 mm sized papillary carcinoma in the right thyroid gland, which showed an intrathyroidal location with no lymph node enlargement on ultrasound. She was not a candidate for thyroid surgery owing to an underlying medical condition,

Received July 15, 2016; accepted after revision July 18, 2016.

Corresponding author: Eun-Kyung Kim, MD, PhD, Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.

• Tel: (822) 2228-2371 • Fax: (822) 393-3035

• E-mail: ekkim@yuhs.ac

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

so the authors chose radiofrequency ablation to treat thyroid cancer.

However, it is my opinion that simple observation for papillary microcarcinoma is more appropriate for management of thyroid cancer in such cases. Papillary microcarcinoma (measuring 10 mm or less) in the absence of other poor prognostic features such as extrathyroidal extension or lymph node metastasis runs an indolent course, so it is a good candidate for observation (2, 3). Ito et al. (4) demonstrated a similar recurrence and mortality rate when these cancers were observed rather than treated with immediate surgery. Moreover, ablating only the primary thyroid carcinoma is not recommended because of a high incidence of multiplicity and lymph node metastasis even though the carcinoma is small in size (4). Recent American Thyroid Association guidelines do not recommend fine needle aspiration in subcentimetric thyroid nodules even with highly suspicious ultrasound patterns (2), and this trend is closely related to a "less is more" paradigm shift in the management of thyroid nodules (5).

REFERENCES

1. Sun J, Liu X, Zhang Q, Hong Y, Song B, Teng X, et al. Papillary thyroid carcinoma treated with radiofrequency ablation in a patient with hypertrophic cardiomyopathy: a case report. *Korean J Radiol* 2016;17:558-561
2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016;26:1-133
3. Scott E, Learoyd D, Clifton-Bligh RJ. Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives. *Future Oncol* 2016 Jul 8 [Epub]. <http://dx.doi.org/10.2217/fon-2016-0171>.
4. Ito Y, Oda H, Miyauchi A. Insights and clinical questions about the active surveillance of low-risk papillary thyroid microcarcinomas [Review]. *Endocr J* 2016;63:323-328
5. Kim BW, Yousman W, Wong WX, Cheng C, McAninch EA. Less is more: comparing the 2015 and 2009 American Thyroid Association guidelines for thyroid nodules and cancer. *Thyroid* 2016;26:759-764